These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Primary SARS-CoV-2 Infections, Re-infections and Vaccine Effectiveness during the Omicron Transmission Period in Healthcare Workers of Trieste and Gorizia (Northeast Italy), 1 December 2021-31 May 2022. Cegolon L; Negro C; Mastrangelo G; Filon FL; Viruses; 2022 Nov; 14(12):. PubMed ID: 36560692 [No Abstract] [Full Text] [Related]
3. COVID-19 in City Council Civil Servants, 1 March 2020-31 January 2023: Risk of Infection, Reinfection, Vaccine Effectiveness and the Impact of Heterologous Triple Vaccination. Cegolon L; Larese Filon F Vaccines (Basel); 2024 Feb; 12(3):. PubMed ID: 38543888 [No Abstract] [Full Text] [Related]
4. COVID-19 Incidence and Vaccine Effectiveness in University Staff, 1 March 2020-2 April 2022. Cegolon L; Negro C; Pesce M; Filon FL Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851360 [No Abstract] [Full Text] [Related]
5. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551 [TBL] [Abstract][Full Text] [Related]
6. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study. Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786 [TBL] [Abstract][Full Text] [Related]
7. Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico. Montes-González JA; Zaragoza-Jiménez CA; Antonio-Villa NE; Fermín-Martínez CA; Ramírez-García D; Vargas-Vázquez A; Gutiérrez-Vargas RI; García-Rodríguez G; López-Gatell H; Valdés-Ferrer SI; Bello-Chavolla OY Front Public Health; 2023; 11():1146059. PubMed ID: 37081954 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022. Hall VJ; Insalata F; Foulkes S; Kirwan P; Sparkes D; Atti A; Cole M; de Lacy E; Price L; Corrigan D; Brown CS; Islam J; Charlett A; Hopkins S; J Infect; 2024 Jan; 88(1):30-40. PubMed ID: 37926119 [TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India. Malhotra S; Mani K; Lodha R; Bakhshi S; Mathur VP; Gupta P; Kedia S; Sankar J; Kumar P; Kumar A; Ahuja V; Sinha S; Guleria R; ; Dua A; Ahmad S; Sathiyamoorthy R; Sharma A; Sakya T; Gaur V; Chaudhary S; Sharma S; Madan D; Gupta A; Virmani S; Gupta A; Yadav N; Sachdeva S; Sharma S; Singh S; Pandey A; Singh M; Jhurani D; Sarkar S; Lokade AK; Mohammad A; Pandit S; Dubey R; Singh AK; Gohar N; Soni D; Bhattacharyya A; Rai S; Tummala S; Gupta I; Shukla S JAMA Netw Open; 2022 Jan; 5(1):e2142210. PubMed ID: 34994793 [TBL] [Abstract][Full Text] [Related]
10. A Multi-Center Study Investigating Long COVID-19 in Healthcare Workers from North-Eastern Italy: Prevalence, Risk Factors and the Impact of Pre-Existing Humoral Immunity-ORCHESTRA Project. Cegolon L; Mauro M; Sansone D; Tassinari A; Gobba FM; Modenese A; Casolari L; Liviero F; Pavanello S; Scapellato ML; Taus F; Carta A; Spiteri G; Monaco MGL; Porru S; Larese Filon F Vaccines (Basel); 2023 Nov; 11(12):. PubMed ID: 38140174 [No Abstract] [Full Text] [Related]
11. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. Carazo S; Skowronski DM; Brisson M; Barkati S; Sauvageau C; Brousseau N; Gilca R; Fafard J; Talbot D; Ouakki M; Gilca V; Carignan A; Deceuninck G; De Wals P; De Serres G Lancet Infect Dis; 2023 Jan; 23(1):45-55. PubMed ID: 36152671 [TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Infection in Health Care Workers of Trieste (North-Eastern Italy), 1 October 2020-7 February 2022: Occupational Risk and the Impact of the Omicron Variant. Cegolon L; Ronchese F; Ricci F; Negro C; Larese-Filon F Viruses; 2022 Jul; 14(8):. PubMed ID: 36016284 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506 [TBL] [Abstract][Full Text] [Related]
14. Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy). Basso P; Negro C; Cegolon L; Larese Filon F Viruses; 2022 Feb; 14(2):. PubMed ID: 35215930 [No Abstract] [Full Text] [Related]
15. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts. Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565 [TBL] [Abstract][Full Text] [Related]
16. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588 [TBL] [Abstract][Full Text] [Related]
18. Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022. Vicentini M; Venturelli F; Mancuso P; Bisaccia E; Zerbini A; Massari M; Cossarizza A; De Biasi S; Pezzotti P; Bedeschi E; Giorgi Rossi P; ; Euro Surveill; 2023 Mar; 28(13):. PubMed ID: 36995374 [TBL] [Abstract][Full Text] [Related]
19. Risk and severity of SARS-CoV-2 reinfections during 2020-2022 in Vojvodina, Serbia: A population-level observational study. Medić S; Anastassopoulou C; Lozanov-Crvenković Z; Vuković V; Dragnić N; Petrović V; Ristić M; Pustahija T; Gojković Z; Tsakris A; Ioannidis JPA Lancet Reg Health Eur; 2022 Sep; 20():100453. PubMed ID: 35791336 [TBL] [Abstract][Full Text] [Related]
20. Incidence, Risk, and Severity of SARS-CoV-2 Reinfections in Children and Adolescents Between March 2020 and July 2022 in Serbia. Medic S; Anastassopoulou C; Lozanov-Crvenkovic Z; Dragnic N; Petrovic V; Ristic M; Pustahija T; Tsakris A; Ioannidis JPA JAMA Netw Open; 2023 Feb; 6(2):e2255779. PubMed ID: 36780157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]